PMID: 8610653Apr 1, 1996Paper

Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma

American Journal of Clinical Oncology
Y H KimJ S Kim

Abstract

A phase II trial was performed with oral UFT plus leucovorin (LV) in 16 patients with advanced gastric carcinoma. Treatment consisted of UFT, 480 mg/m(2)/day, in conjunction with LV administered at 25 mg/m(2)/day per os in divided daily doses for 21 days followed by a 7-day rest period. The median age of patients was 64 years, with a median World Health Organization (WHO) performance status of 2. One patient was previously treated with etoposide, doxorubicin, and cisplatin (EAP). A median of four courses of treatment were given per patient (range: 1-9). Among 14 evaluable patients, one patient achieved a complete response and 3 had partial responses (response rate: 28.5%, 95% confidence interval, 4.9 to 52.3%). Stable disease was reported in 5 patients (35.7%) and another 5 showed progression. The time to progression was 17, 18, 27, and 76+ weeks for the responding patients, respectively. The median duration of survival was 25 weeks (range: 10-76+) for 14 evaluable patients. All patients were evaluable for toxicity. The main toxicity was diarrhea and oral mucositis. Significant toxicity (WHO grade 3 or 4) included diarrhea in 7 patients (43.8%), oral mucositis in 2 (12.5%), and nausea/vomiting in 2, respectively. We conclude th...Continue Reading

References

Jan 1, 1979·Annals of Surgery·K AdashekW P Longmire
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J O'Connell
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D KelsenM Brennan
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·K OtaK Kimura
Apr 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Y BedikianG P Bodey
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T R BurokerD H Gesme
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R PazdurB Bready
Jan 1, 1994·CA: a Cancer Journal for Clinicians·C C BoringS Montgomery

❮ Previous
Next ❯

Citations

Jul 6, 2010·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Ester J M SiemerinkGeke A P Hospers
Aug 5, 2011·Drugs·Jaclyn YoongTrevor Leong
Apr 15, 2008·Future Oncology·Jae-Lyun Lee, Yoon-Koo Kang
Apr 1, 2005·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Yeul Hong Kim
Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A RavaudUNKNOWN EORTC-ECSG
Jun 15, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alicia F C Okines, David Cunningham
Dec 8, 2009·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·A YoneyM Unsal
Jun 16, 2001·Current Problems in Cancer·C H Takimoto
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Alicia OkinesDavid Cunningham
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S S WöhrerM Hejna
Jan 30, 2015·World Journal of Gastroenterology : WJG·Sevgi OzdenAlpaslan Mayadagli
Feb 19, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N F Aykan, E Idelevich

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
A RavaudEORTC-ECSG
Annals of Oncology : Official Journal of the European Society for Medical Oncology
N F Aykan, E Idelevich
The New England Journal of Medicine
Shinichi SakuramotoACTS-GC Group
© 2021 Meta ULC. All rights reserved